Stocks and Investing Stocks and Investing
Fri, May 31, 2019
Thu, May 30, 2019

Jason Gerberry Downgraded (TEVA) to Sell and Decreased Target to $9 on, May 30th, 2019


Published on 2024-10-26 13:57:32 - WOPRAI, Jason Gerberry
  Print publication without navigation


Jason Gerberry of B of A Securities, Downgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Sell and Decreased Target from $19 to $9 on, May 30th, 2019.

Jason has made no other calls on TEVA in the last 4 months.



There are 6 other peers that have a rating on TEVA. Out of the 6 peers that are also analyzing TEVA, 4 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kevin Caliendo of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $12 on, Tuesday, May 28th, 2019
  • Jacob Hughes of "Wells Fargo" Maintained at Hold with Decreased Target to $17 on, Thursday, May 9th, 2019
  • David Risinger of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $17 on, Wednesday, March 6th, 2019
  • Vamil Divan of "Credit Suisse" Maintained at Hold with Decreased Target to $20 on, Thursday, February 14th, 2019


These are the ratings of the 2 analyists that currently disagree with Jason


  • Liav Abraham of "Citigroup" Maintained at Strong Buy with Decreased Target to $23 on, Thursday, April 11th, 2019
  • Elliot Wilbur of "Raymond James" Upgraded from Hold to Buy on, Thursday, February 14th, 2019
Contributing Sources